A clinical formulation indicated for HIV. This medicinal support assists with inhibiting essential viral enzymes to promote suppressed viral activity within the host.
Indicated to manage HIV-1 by addressing viral protease activity to support immune function and mitigate the progression of chronic infection in adult patients.
Mechanism of Action
Darunavir is a protease inhibitor. It blocks the HIV enzyme protease, which the virus needs to cut long protein chains into smaller functional pieces to build new viruses, preventing viral replication.
Route of Administration
Oral
Onset Time
Steady state in 2 days
Duration
12–24 hours
Contraindications
Severe hepatic impairment, Concurrent use with drugs that induce CYP3A (e.g., rifampin, St. John's Wort), Known sulfa allergy (caution)
Severe Adverse Events
Hepatoxicity, Severe skin reactions (SJS), Diabetes onset or worsening, Immune reconstitution syndrome, Increased bleeding in hemophilia
Information for Darunavir is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
